WallStreetZenWallStreetZen

NASDAQ: ATYR
Atyr Pharma Inc Stock

$1.90-0.05 (-2.56%)
Updated Jun 12, 2024
ATYR Price
$1.90
Fair Value Price
N/A
Market Cap
$131.12M
52 Week Low
$1.08
52 Week High
$2.45
P/E
-2.11x
P/B
1.55x
P/S
219.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$588.00k
Earnings
-$53.93M
Gross Margin
100%
Operating Margin
-9,171.6%
Profit Margin
-9,171.6%
Debt to Equity
0.34
Operating Cash Flow
-$55M
Beta
0.83
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ATYR Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATYR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATYR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATYR is good value based on its book value relative to its share price (1.55x), compared to the US Biotechnology industry average (6.31x)
P/B vs Industry Valuation
ATYR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATYR due diligence checks available for Premium users.

Be the first to know about important ATYR news, forecast changes, insider trades & much more!

ATYR News

Valuation

ATYR fair value

Fair Value of ATYR stock based on Discounted Cash Flow (DCF)
Price
$1.90
Fair Value
$0.12
Overvalued by
1,540.11%
ATYR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATYR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.11x
Industry
-9.14x
Market
30.03x

ATYR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.55x
Industry
6.31x
ATYR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATYR's financial health

Profit margin

Revenue
$235.0k
Net Income
-$15.5M
Profit Margin
-6,591.9%
ATYR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATYR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$113.3M
Liabilities
$29.0M
Debt to equity
0.34
ATYR's short-term assets ($96.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATYR's short-term assets ($96.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATYR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATYR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$22.4M
Investing
-$1.4M
Financing
$7.7M
ATYR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATYR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATYR$131.12M-2.56%-2.11x1.55x
CRDF$131.94M0.00%-3.28x2.17x
VERU$130.14M-4.31%-2.61x2.88x
ANL$132.71M+8.76%-0.50x1.67x
CRVS$129.48M-3.27%-4.06x3.88x

Atyr Pharma Stock FAQ

What is Atyr Pharma's quote symbol?

(NASDAQ: ATYR) Atyr Pharma trades on the NASDAQ under the ticker symbol ATYR. Atyr Pharma stock quotes can also be displayed as NASDAQ: ATYR.

If you're new to stock investing, here's how to buy Atyr Pharma stock.

What is the 52 week high and low for Atyr Pharma (NASDAQ: ATYR)?

(NASDAQ: ATYR) Atyr Pharma's 52-week high was $2.45, and its 52-week low was $1.08. It is currently -22.45% from its 52-week high and 75.93% from its 52-week low.

How much is Atyr Pharma stock worth today?

(NASDAQ: ATYR) Atyr Pharma currently has 69,010,940 outstanding shares. With Atyr Pharma stock trading at $1.90 per share, the total value of Atyr Pharma stock (market capitalization) is $131.12M.

Atyr Pharma stock was originally listed at a price of $209.30 in May 7, 2015. If you had invested in Atyr Pharma stock at $209.30, your return over the last 9 years would have been -99.09%, for an annualized return of -40.69% (not including any dividends or dividend reinvestments).

How much is Atyr Pharma's stock price per share?

(NASDAQ: ATYR) Atyr Pharma stock price per share is $1.90 today (as of Jun 12, 2024).

What is Atyr Pharma's Market Cap?

(NASDAQ: ATYR) Atyr Pharma's market cap is $131.12M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Atyr Pharma's market cap is calculated by multiplying ATYR's current stock price of $1.90 by ATYR's total outstanding shares of 69,010,940.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.